Perspectives - Page 16

Strategic Assessment of a New Treatment for Central Nervous System (CNS) Cancers

Lumanity's Clinical & Regulatory team analyzed the regulatory and clinical development considerations for a new asset.

Case Study Jun 5, 2023

Medical Affairs Unscripted | Investing in Medical Affairs with John Yee, MD, MPH

Podcast Jun 1, 2023

Overcoming Challenges in Demonstrating the Value of Drugs for Treating Rare Diseases

Whitepaper May 31, 2023

Developing an Above Therapy Area Proposition and Communication Framework

Case Study May 30, 2023

Bridging the Gap in Translation and Innovation: Oncology’s Probability of Success (PoS) Problem

View May 23, 2023

Long-term Partnership Resulting in Successful Re-submission to NICE Increasing Patient Access to a Treatment for Diabetic Macular Edema

We supported AbbVie with global evidence generation and an initial submission to the National Institute for Health and Care Excellence (NICE) in 2015 for a treatment for diabetic macular oedema – the leading cause of sight loss in people with diabetes.

Case Study May 19, 2023

ISPOR Diaries 2023

View May 19, 2023

Medical Affairs Unscripted Podcast Bytes | The Digital Transformation of Medical Affairs with Janet Loesberg, PharmD

Podcast May 18, 2023

Updates on Over the Counter Monograph Reform in the CARES Act

View May 10, 2023

The Growing Pipeline of First-Time Commercializers and the Challenges of New Enterprise Commercialization

On-Demand Webinar May 9, 2023

Launch Excellence Alchemy | Collaboration Mindset, Leadership, and the Value of a ‘Third Voice’

Join Tracey Barnes, Vice President of Launch Excellence at Lumanity, and Ollie Roberts, Pharma Launch Expert, as they discuss the critical steps to becoming a better launch collaborator.

Podcast May 9, 2023

Possible Implications of the Inflation Reduction Act for Oncology Products and Stakeholders

Podcast May 2, 2023

Medical Affairs Unscripted | Medical Affairs Leadership – Breaking Through Barriers to Success with Janet Loesberg, PharmD

Podcast Apr 28, 2023

The EU HTA Regulation

View Apr 27, 2023

On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions

On-Demand Webinar Apr 26, 2023

Using Real-World Data in the Health Technology Assessment of Pharmaceuticals

n a five article series published in leading health economics and outcomes research (HEOR) journal, Value in Health, Lumanity HEOR Executive Chair, Ron Akehurst, and Senior Director, Linda Murphy, collaborate with other industry experts to identify obstacles to the optimal use of RWE in HTA, and also present detailed solutions.

View Apr 20, 2023